LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

BioCryst Pharmaceuticals Inc

Suletud

SektorTervishoid

8.28 -0.24

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.27

Max

8.46

Põhinäitajad

By Trading Economics

Sissetulek

5.1M

5.1M

Müük

18M

163M

Kasumimarginaal

3.113

Töötajad

580

EBITDA

-84M

-62M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+110.59% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

3. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-36M

1.8B

Eelmine avamishind

8.52

Eelmine sulgemishind

8.28

Uudiste sentiment

By Acuity

25%

75%

50 / 371 Pingereas Healthcare

BioCryst Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. sept 2025, 11:09 UTC

Suurimad hinnamuutused turgudel

Indonesia's Political Turmoil Rattles Stock, Currency Markets -- Update

1. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. sept 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

1. sept 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

1. sept 2025, 16:08 UTC

Market Talk

Gold Futures Rise on Rate Cut Hopes, Geopolitical Tensions -- Market Talk

1. sept 2025, 15:21 UTC

Market Talk

Path Still Open for Bank of England November Rate Cut -- Market Talk

1. sept 2025, 15:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. sept 2025, 15:12 UTC

Omandamised, ülevõtmised, äriostud

CoreWeave Faces a Fight to Buy Core Scientific Amid Stock Shifts. Why a Deal Needs to Be Done. -- Barrons.com

1. sept 2025, 14:09 UTC

Market Talk

U.S. Jobs Data Could Offer Some Respite to Dollar -- Market Talk

1. sept 2025, 14:00 UTC

Market Talk

Silver Prices Reach 14-Year High on Rate Cut Bets, Industrial Demand -- Market Talk

1. sept 2025, 12:20 UTC

Market Talk

Sterling Faces Hit From Unfavorable Inflation, Growth Mix -- Market Talk

1. sept 2025, 12:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. sept 2025, 11:42 UTC

Market Talk

Growth Forecasts Are Driving Dollar -- Market Talk

1. sept 2025, 11:31 UTC

Market Talk

U.K. Sovereign Bond Yields Remain Highest in Developed Markets -- Market Talk

1. sept 2025, 11:27 UTC

Market Talk

U.K. Credit Flows Signal Confidence Among Households -- Market Talk

1. sept 2025, 11:24 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1. sept 2025, 11:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. sept 2025, 11:24 UTC

Market Talk

Dollar Could Show Mixed Reaction if Court Ruling Against Trump's Tariffs is Upheld -- Market Talk

1. sept 2025, 11:12 UTC

Market Talk

Ukrainian Strikes Could Shift Russia's Oil Export Patterns -- Market Talk

1. sept 2025, 11:03 UTC

Market Talk

Oil Rises Amid Weaker Dollar, Russian Supply Risks -- Market Talk

1. sept 2025, 10:58 UTC

Tulu

BYD Stock Plummets. How China's EV Price War Tanked Tesla Rival's Earnings. -- Barrons.com

1. sept 2025, 10:39 UTC

Market Talk

U.K.'s High Rates Still Hold Back Economy -- Market Talk

1. sept 2025, 10:34 UTC

Market Talk

Weak Jobs Data Would Likely Trigger Further Dollar Losses -- Market Talk

1. sept 2025, 10:25 UTC

Market Talk

Base Metal Prices Mixed in Low-Volume Trading -- Market Talk

1. sept 2025, 10:17 UTC

Market Talk

Focus on U.S. Jobs Data This Week for Clues on Rate-Cut Prospects -- Market Talk

1. sept 2025, 09:31 UTC

Market Talk
Tulu

Societe Generale's Self-Improvement Story Insulated From External Turbulences -- Market Talk

1. sept 2025, 09:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. sept 2025, 09:08 UTC

Market Talk

Euro Lifted by Weaker Dollar, Prospect of ECB Ending Rate Cuts -- Market Talk

1. sept 2025, 08:52 UTC

Market Talk

U.K. Miners Rise as Gold Prices Buoyed by Potential U.S. Rate Cut, Tariff Uncertainty -- Market Talk

Võrdlus sarnastega

Hinnamuutus

BioCryst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

110.59% tõus

12 kuu keskmine prognoos

Keskmine 17.5 USD  110.59%

Kõrge 30 USD

Madal 12 USD

Põhineb 6 Wall Streeti analüütiku instrumendi BioCryst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

50 / 371 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.